Trajenta tragedy drags on as G-BA bags gliptins that nipped in before
This article was originally published in Scrip
Executive Summary
The G-BA, the body in charge of Germany's new and much maligned early benefit assessment, is to retroactively appraise drugs in the gliptin class that were already on the market before the healthcare reform law (AMNOG) came into force. This could be bad news for the drugs, including Merck's Januvia (sitagliptin), Novartis' Galvus (vildagliptin) and Eucreas (vildagliptin/metformin) as well as Bristol-Myers Squibb/AstraZeneca's Onglyza (saxagliptin). The drugs are likely to face the same hurdles that prompted Boehringer Ingelheim to withdraw its gliptin, Trajenta.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.